NEW YORK, Nov. 13, 2015 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq:NDAQ) announced that trading of Mesoblast Limited (Nasdaq:MESO) commenced on The Nasdaq Stock Market on November 13, 2015.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/0e342f61-59da-4b4d-acf4-b6d94134fe66
Mesoblast is a world leader in the development of innovative cell-based medicines based on its proprietary allogeneic, off-the-shelf mesenchymal lineage cell-based technology. The Company has established a diverse portfolio of product candidates, with multiple active Phase 3 clinical programs. The Company’s lead product candidates target major diseases with significant unmet medical needs despite existing therapies. These include chronic heart failure, chronic low back pain due to degenerative disc disease, and immune-mediated conditions such as acute graft versus host disease (GVHD) and biologic refractory rheumatoid arthritis. Mesoblast has established multiple strategic partnerships, including in Japan for GVHD where its licensee has most recently received the first full Japanese Government regulatory approval for an allogeneic cell-based product.
“With its clinically advanced and diverse portfolio of cell-based product candidates, Mesoblast is an innovator in its field,” said Nelson Griggs, Executive Vice President, Listing Services, Nasdaq. “We are excited to welcome Mesoblast to our family of listed companies.”
By listing on Nasdaq, Mesoblast joins many of the world’s largest and most revolutionary companies. Nasdaq is the exchange of choice for 78 percent of healthcare companies that have listed on the U.S. markets year-to-date.
The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither Nasdaq nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.
About Mesoblast Limited:
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) is a global leader in regenerative medicine. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases where there are highly unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncology/hematology conditions.
Nasdaq, Inc. (Nasdaq:NDAQ) is a leading provider of trading, clearing, exchange technology, listing, information and public company services across six continents. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 70 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to more than 3,600 listed companies with a market value of approximately $8.8 trillion and more than 10,000 corporate clients. To learn more, visit: nasdaq.com/ambition or business.nasdaq.com.
The photo is also available via AP PhotoExpress.
Media Relations Contacts: Will Briganti (646) 441-5012 email@example.com